Results 171 to 180 of about 77,701 (209)

Tacrolimus Induced Hypertension and Vascular Remodeling Includes Mechanisms of Cellular Senescence-The Protective Effect of Valsartan. [PDF]

Acta Physiol (Oxf)
Fei L, Wang X, Kong L, Cui T, Khedkar PH, Xiang Y, Zhao D, Fang J, Liang Y, Zhang Y, Xu N, Qiu X, Zhao L, Zhang G, Lei Y, Tang C, Ma K, Lu L, Wei J, Lai EY, Persson PB, Patzak A, Zheng Z, Jiang S.   +23 more
europepmc   +1 more source

Effect of SGLT2 Inhibitors on Atrial Fibrillation in Patients With Type 2 Diabetes With Dilated Cardiomyopathy: A Cohort Study. [PDF]

Cardiovasc Ther
Wang J, Qi S, Chen S, Yu H.
europepmc   +1 more source

Incidence and outcomes of diabetes mellitus amongst hospital admissions with <i>de novo</i> heart failure; a retrospective cohort study from a nationwide registry. [PDF]

Front Clin Diabetes Healthc
Chapra A, Kaddoura R, Patel A, Francis T, Varghese S, Mohamed Ibrahim MI, Shah J, Alsadi H, Elasfar A, Badr A, Singh R, Arabi A.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The angiotensin II type 1 receptor blocker valsartan attenuates graft vasculopathy

Basic Research in Cardiology, 2004
Transplant arteriosclerosis remains the major cause of graft failure after cardiac transplantation. Here, we investigated the effects of the angiotensin II type 1 receptor blocker valsartan on the development of transplant arteriosclerosis in a murine model of cardiac transplantation.Hearts from DBA/2 (H-2(d)) mice were heterotopically transplanted ...
Tetsufumi, Yamamoto, Masataka, Sata, Daiju, Fukuda, Shinichi, Takamoto   +3 more
openaire   +3 more sources

Angiotensin‐converting enzyme inhibitors and angiotensin II type 1 receptor blockers after renal transplantation

Clinical Transplantation, 2009
Abstract:  Renin‐angiotensin system blockade retards the progression of diabetic and non‐diabetic chronic kidney disease of the native kidneys. Though most patients suffer from a significant renal insufficiency (chronic kidney disease stage III) and a concomitant heart disease after renal transplantation, there is up to now no evidence supporting the ...
C, Morath, B, Schmied, A, Mehrabi, J, Weitz, J, Schmidt, J, Werner, M W, Buchler, M, Morcos, P P, Nawroth, V, Schwenger, B, Doehler, G, Opelz, M, Zeier   +12 more
openaire   +2 more sources

Effect of angiotensin II type 1 receptor blocker on osteoporotic rat femurs

Pharmacological Reports, 2012
Osteoblasts and osteoclasts are known to express Ang II type I (AT1) receptor in cell cultures, suggesting the existence of local renin-angiotensin system (RAS) in bone. This study was designed to investigate the effects of losartan as AT1 receptor blocker on ovariectomized rats' femur.Losartan (5 mg/kg/day) was administered via oral gavage for 8 weeks.
Ozdemir S., Donmez B.O., Sarikanat M., Yaras N., Koc P., Demir N., Karayalcin B., Oguz N.   +7 more
openaire   +2 more sources

Class- and Molecule-specific Differential Effects of Angiotensin II Type 1 Receptor Blockers

Current Pharmaceutical Design, 2013
Angiotensin II (Ang II) type 1 (AT1) receptor is a member of the G protein-coupled receptor superfamily and contains 359 amino acids. AT1 receptor blockers (ARBs, e.g., eprosartan, losartan, candesartan, valsartan, telmisartan, olmesartan, irbesartan, and azilsartan) have been developed and are available for clinical use, and basic and clinical studies
Satoshi, Imaizumi, Shin-ichiro, Miura, Eiji, Yahiro, Yoshinari, Uehara, Issei, Komuro, Keijiro, Saku   +5 more
openaire   +2 more sources

Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different?

The American Journal of Cardiology, 1999
The angiotensin II receptor blockers (ARBs) are safe and effective agents in the treatment of hypertension, and they have potential in treating other cardiovascular disorders such as heart failure. These drugs share a common mechanism of action: They selectively block the angiotensin type 1 (AT1) receptor.
openaire   +2 more sources

Possible benefits of azilsartan compared with other angiotensin II type 1 receptor blockers

Hypertension Research, 2014
Possible benefits of azilsartan compared with other angiotensin II type 1 receptor ...
Shin-Ichiro, Miura, Keijiro, Saku
openaire   +2 more sources